Payment overview · 2025
General Payments
$404.89
18 reported records · 12 companies
Healthcare provider profile · identity verified
Chang Xia, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · SYLVANIA, OH · NPI 1114187549
Verified facts
What the public records show
CMS Open Payments records show Chang Xia, M.D. received $404.89 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kisqali, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Venclexta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lenvima by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kisqali by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.05 | 22.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.31 | 20.8% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.78 | 7.4% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $29.62 | 7.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.94 | 6.4% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.32 | 6.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.27 | 5.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.74 | 5.4% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $21.55 | 5.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.32 | 5.0% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $18.65 | 4.6% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $16.34 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.89 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $57.23 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KISQALI kisqali |
2025 | Kisqali | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 17 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Letrozole | Letrozole | 324 | 111 |
| Prednisone | Prednisone | 115 | 38 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 115 | 70 |
| Eliquis | Apixaban | 107 | 17 |
| Tamoxifen Citrate | Tamoxifen Citrate | 102 | 37 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Gabapentin | Gabapentin | 88 | 19 |
| Anastrozole | Anastrozole | 75 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 20 |
| Abiraterone Acetate | Abiraterone Acetate | 67 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 40 |
| Dexamethasone | Dexamethasone | 58 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 13 |
| Hydroxyurea | Hydroxyurea | 53 | 17 |
| Klor-Con M20 | Potassium Chloride | 48 | 13 |
| Lorazepam | Lorazepam | 38 | 19 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | suppressed |
| Lenalidomide | Lenalidomide | 34 | suppressed |
| Revlimid | Lenalidomide | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 17 |
| Acyclovir | Acyclovir | 31 | suppressed |
| Furosemide | Furosemide | 29 | 19 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 29 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 13 |
| Imbruvica | Ibrutinib | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 17 |
| Kisqali | Ribociclib Succinate | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Venclexta | Venetoclax | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | 13 |
| Ninlaro | Ixazomib Citrate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Nubeqa | Darolutamide | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Calquence | Acalabrutinib Maleate | 11 | suppressed |
| Lenvima | Lenvatinib Mesylate | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Venclexta Starting Pack | Venetoclax | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.89 · 18 records | AstraZeneca Pharmaceuticals LP | DANZITEN, ENHERTU, FOTIVDA, IMFINZI, KEYTRUDA, KISQALI, LUTATHERA, MONJUVI, NERLYNX, Odomzo, PLUVICTO, Polivy, REBLOZYL, RYBREVANT, VENCLEXTA, YONSA, ZYNYZ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kisqali play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error